Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biotech's wellspring: a survey of the health of the private sector

An examination of the private biotech industry reveals shrinking financial resources and higher hurdles to obtain funding, but new models are evolving to meet the challenge.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Global venture funding of private biotech companies, 2001–2011.
Figure 2: Venture capital investment for biotechnology therapeutic companies.
Figure 3: Top university patent assignees.

Author information

Authors and Affiliations


Supplementary information

Supplementary Text and Figures

Supplementary Figure 1 and Supplementary Tables 1-8 (XLSX 63 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Huggett, B. Biotech's wellspring: a survey of the health of the private sector. Nat Biotechnol 30, 395–400 (2012).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research